Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Low volume so far.
Which way is this thing gonna turn end of day? Crash back down to even or spike up to $0.62+? Someone is likely going to try to influence tomorrow with such low volume.
I understand your optimism Doc but there is absolutely no way NWBO gets anywhere close to 'breakeven', which in actuality is well over the $30M you are budgeting for Advent, this year.
I expect approval this year, but I will be absolutely stunned if NWBO's revenue increases even 5x, which would put them around $5M.
$30M in 5 months is just not how these things ramp up.
Real, material revenue is scheduled for 2025. Saying or trying to get people to expect any sooner than that is hopium and irresponsible. Be realistic.
Up 8% on a little 4k trade premarket.
These usually don't hold, but....interesting.
Hey Kab - what's up with all the juvenile name calling today? Are you having anger management problems or are you simply stuck in your teens WRT your social development? Just to offer some free advice - that's a stunningly bad look.
The potty-mouth, content-free schoolyard name-calling is not an adult way to communicate. To the extent adults use it, it's low class. Why would you want to escalate disagreements to the most ad hominem possible level? It doesn't do anything to make you look smart and it undermines any good-faith attempts at communication. It's bad for your discussion and encourages the degradation of the message board. It's not clever at all and is deeply offensive no matter whom you are addressing.
Just to be clear I'm talking about the following which you wrote today:
Not at all what I said.
Strawman.
Oh my word - a company that successfully commercialized a product taking the profits from that product and reinvesting them to grow their R&D pipeline, which in turn creates more commercial products and more profit?
The horror!
Sprinkbok is a narrow minded bully with no capacity to comprehend healthy discussion.
Haha, what?? C'mon Ex. Try harder. Biosimilar evaluation exists because different suppliers use different manufacturing processes to develop biosimilars of reference products. It's literally the exact opposite of what you are saying. The purpose is to make sure biosimilars function the same as an RP even though they may use a different manufacturing process.
What is a biosimilar medicine (direct from MHRA):
I was sarcastically poking at posters that have tried to knock Flaskworks by saying that the comparability studies will essentially require another trial.
"They're going to have to do a whole additional comparability trial before they can use Flaskworks for DCVax"
7000 share premarket trade up.
"move the price up" signal.
Interdasting.
Aww, sad that I am still here decimating your arguments?
Riddle me this, batman.
If the deferral to start after submission inherently implies that it must still start prior to approval, why does the MHRA state this with regards to deferrals: